The Cabilly patents are two US patents issued to Genentech and City of Hope which relate to the "fundamental technology required for the artificial synthesis of antibody molecules." The name refers to lead inventor Shmuel Cabilly, who was awarded the patent while working at City of Hope in the 1980s. There was ongoing legal controversy surrounding these patents since their original filing in 1983. In 2008, the litigation that was pending before the U.S. District Court for the Central District of California, was fully resolved and dismissed.
